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Background and aims: This review appraises the progression and status of the evidence base for the treatment of
compulsive buying disorder (CBD), in order to highlight what currently works and to prompt useful future research.
Methods: Online databases ISI Web of Knowledge, PsycINFO, and PubMed via Ovid were searched at two time
points. Two quality checklists and an established model of therapy evaluation (hourglass model) evaluated the quality
and progression of both psychotherapy and pharmacotherapy treatments for CBD. Uncontrolled effect sizes were
calculated and meta-regression analyses were performed regarding treatment duration. Results: A total of 29 articles
met the inclusion criteria, which were divided into psychotherapy (n= 17) and pharmacotherapy treatments (n= 12).
Of the 29 studies, only 5 studies have been tested under conditions of high methodological quality. Both forms of
treatment had been evaluated in a haphazard manner across the stages of the hourglass model. Although large effects
were demonstrated for group psychotherapy and pharmacotherapy, such evidence of effectiveness was undermined
by poor study quality and risk of publication bias. Long-term CBD treatment was associated with improved outcome
with pharmacotherapy, but not when delivering psychotherapy. Discussion: Group psychotherapy currently appears
the most promising treatment option for CBD. Poor methodological control and sporadic evaluation of speciﬁc
treatments have slowed the generation of a convincing evidence base for CBD treatment. Deﬁning the active
ingredients of effective CBD treatment is a key research goal.
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BACKGROUND AND AIMS
Compulsive buying disorder (CBD) is characterized by
excessive or poorly controlled preoccupations, urges, or
behaviors regarding shopping and spending, which leads
to adverse consequences (Black, 2007). CBD is distin-
guished by a motivation to feel better, rather than from
excessive spending and materialism alone (O’Guinn &
Faber, 1989), often creating serious associated impacts on
lives, such as substantial debt, relationship problems, ele-
vated risk of criminal behavior, and suicide attempts (Black,
2007; Boundy, 2000; Lejoyeux, Tassain, Solomon, & Adès,
1997; O’Guinn & Faber, 1989).
CBD was included in the earliest attempts at classiﬁcation
of mental disorders as “impulsive insanity” (Bleuler, 1930;
Kraepelin, 1915), but has since been largely ignored until the
last few decades, when the self-help movement testiﬁed to
the emotional, ﬁnancial, and interpersonal impacts of CBD
(Benson, 2000; Faber, 2011). Categorization of CBD still
remains a debate, reinforced by its omission in the most
recent edition of the Diagnostic and Statistical Manual
(DSM-5; American Psychiatric Association, 2013). Histori-
cally, CBD was classiﬁed within the DSM-III-R as an
example of an impulse control disorder not elsewhere speci-
ﬁed (American Psychiatric Association, 1987). CBD has also
been conceptualized as a form of obsessive–compulsive
disorder, and thus, CBD has been characterized as existing
on the impulsive–compulsive spectrum (Frost, Kim, Morris,
Bloss, & Murray-Close, 1998). More recently, research has
indicated correlates of behavioral addictions like cue reac-
tivity and cravings (Starcke, Schlereth, Domass, Schöler, &
Brand, 2013; Trotzke, Starcke, Pederson, & Brand, 2014),
adding further debate to the categorization of CBD.
The development of a clinical screening tool for CBD has
supported the progression of epidemiological research
(Faber & O’Guinn, 1992). A recent meta-analysis of 49
prevalence estimates from 16 countries produced a pooled
prevalence estimate of 4.9% for CBD (Maraz, Grifﬁths, &
Demetrovics, 2016). Early research indicated a higher pro-
portion of females than males meeting criteria (Christenson
et al., 1994; Dittmar, 2005), though recent larger studies have
evidenced an equal gender distribution (Koran, Faber, Abou-
jaoude, Large, & Serpe, 2006; Mueller et al., 2010). Epide-
miological research has also indicated that CBD is associated
with high rates of psychiatric comorbidity with both
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depression (Mueller et al., 2010) and anxiety (Schlosser,
Black, Repertinger, & Freet, 1994), with base rates higher
than when compared with the general population (Black,
Repertinger, Gaffney, & Gabel, 1998). Steffen and Mitchell
(2011) noted that CBD outcome research beneﬁted from the
development of the Yale–Brown Obsessive Compulsive
Scale-Shopping Version (YBOCS-SV; Monahan, Black,
& Gabel, 1996). This is because the YBOCS-SV provides
a psychometrically robust and sensitive measure of change
during CBD treatment (Black, Gabel, Hansen, & Schlosser,
2000; Black, Monaghan, & Gabel, 1997).
Despite increased clarity regarding the phenomenology of
CBD, no evidence-based treatments have emerged (Black,
2007). Lourenço Leite, Pereira, Nardi, and Silva (2014)
conducted a qualitative review of psychotherapeutic treat-
ments for CBD, supporting the potential for cognitive
behavioral group therapy. However, the effectiveness or
quality of the psychotherapy studies was not quantitatively
examined in that review. Moreover, pharmacotherapy of
CBD constitutes a signiﬁcant proportion of the treatment
evidence base (Aboujaoude, 2014; Steffen &Mitchell, 2011)
and this type of intervention was omitted from the Lourenço
Leite et al.’s (2014) review. This review therefore sought to
gain greater clarity concerning the quality and effectiveness
of both psychotherapy and pharmacotherapy treatments of
CBD in order to guide clinicians regarding treatment allo-
cation and to stimulate further targeted research.
The “hourglass model” is a recognized framework for
supporting the appropriate stage development of treatments
and therapies (Salkovskis, 1995) andhas previously beenused
to evaluate a psychotherapy evidence base (see Calvert &
Kellett, 2014 for an example). In stage 1 of the hourglass
model, small practice-based treatment studies (e.g., small N
designs) demonstrate proof of concept. In stage 2, treatments
are then tested under controlled conditions with larger
samples, strict criteria for inclusion, and standardized mea-
surement. Efﬁcacy research designs (such as randomized
controlled and deconstruction trials) at stage 2 reﬁne the focus
of key ingredients ﬁrst found in the exploratory research. In
the ﬁnal stage, large-scale practice-based research evaluates
the effectiveness of treatment in routine clinical practice and is
conducted across multiple sites. The framework is also pur-
posefully cyclical, to be responsive to any conceptual or
treatment limitations unearthed. Due to the relative infancy
of CBD outcome research, the hourglass model is also used
here to indicate and promote appropriate progression of safe
and effective treatments. The speciﬁc aims of this reviewwere
to (a) assess the quality of CBD outcome research,
(b) synthesize the progression of CBD outcome research
according to the stages of the hourglass model, (c) compare
the effectiveness of CBD treatments, (d) illuminate the devel-
opmental areas for CBD models, and (e) deﬁne the best
practice regarding future research methodologies.
METHODS
Literature search
Relevant literature was identiﬁed by (a) searching online
databases ISI Web of Knowledge, PsycINFO, and PubMed
via Ovid search tools on February 1, 2014, (b) searching
article reference lists and citation in the extracted articles,
and (c) contacting authors for studies in press (Figure 1).
The following keywords were used in each database in a
range of combinations: “compulsive buying,” “pathological
buying,” “shopping addiction,” “oniomania,” “overspend-
ing,” and “treatments” or “exp. Psychotherapy” or “inter-
ventions.” Moreover, the asterisk function was used to
capture the differences in spelling between the UK and the
US and also to consider variations (e.g., “buy*” to capture
buying and buyers). Initial search titles and abstracts pro-
vided 244 studies from ISI Web of Knowledge, 98 studies
from PubMed, and 609 studies from PsycINFO. After
duplicates were removed and titles were screened for rele-
vance, 225 articles were considered using the following
inclusion criteria: (a) treatment was described in the design;
(b) treatment primarily targeted compulsive buying; and
(c) articles published in English. After screening full arti-
cles, 24 studies met the inclusion criteria. No further exclu-
sion ﬁlter was imposed due to the low number of CBD
treatment studies. A further four studies were included
following the correspondence with key authors. An updated
search was conducted on August 6, 2015 using the same
search criteria, and a further one study was found and
included in this review.
Data synthesis
Both qualitative and quantitative data syntheses were con-
ducted on the extracted articles. First, standardized quality
ratings assessed the methodological quality of extracted
studies. Second, a narrative synthesis of the outcome re-
search was employed, structured by stages of the hourglass
model (Salkovskis, 1995). Third, effect sizes of CBD out-
comes were calculated in order to enable effectiveness
comparisons, meta-regressions were computed to assess
associations between treatment duration and effect size, and
funnel plots examined potential publication bias.
Quality ratings. Two quality ratings assessed the meth-
odological quality of studies. First, the Downs and Black
(1998) checklist provides a standardized score (0–32) from a
list of 27 criteria and is a valid and reliable tool to assess
randomized and non-randomized studies (Brouwers et al.,
2005; Deeks et al., 2003). As the checklist is difﬁcult to use
with case-controlled studies (Higgins et al., 2011), the tool
was modiﬁed to a 28-criteria scale. Adapted versions of the
checklist have been used in previous systematic reviews,
where randomized controlled trials (RCTs) are few in
number (e.g., MacLehose et al., 2000; Samoocha,
Bruinvels, Elbers, Anema, & van der Beek, 2010; Sohanpal,
Hooper, Hames, Priebe, & Taylor, 2012). Speciﬁcally, the
scoring for question 27 dealing with statistical power was
simpliﬁed to a choice of awarding either 1 or 0 point
depending on the presence of a power analysis. A score of
17 points or more identiﬁed studies of high methodological
quality (Brouwers et al., 2005). Second, the Critical Apprai-
sal Skills Program (CASP UK, 2010) assessed the method-
ological quality according to speciﬁc research design
(e.g., RCTs, case-controlled studies, and qualitative stud-
ies). For this review, all studies were scored by the ﬁrst
author and 4 of the 29 (14%) studies were selected at
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random and scored by an independent rater. Good inter-rater
reliability was achieved on Downs and Black (1998) check-
list ratings (K= 0.67; Altman, 1991), with moderate agree-
ment on CASP ratings (K= 0.51; Altman, 1991).
Calculating and considering effect sizes. Outcome stud-
ies are summarized via forest plot analysis to provide a
visual representation of the average effect sizes across the
studies and enable comparisons of effectiveness between
psychotherapy and pharmacotherapy for CBD. Studies were
included in the forest plot analysis that (a) reported mean
and standard deviations of outcomes at pre- and post-
treatment and associated sample sizes, (b) employed the
YBOCS-SV (Monahan et al., 1996) as the primary outcome
measure, and (c) recruited samples larger than N= 1. Pre–
post ES calculations were undertaken using STATA v.10
(StataCorp, 2007) dividing the mean pre- to post-treatment
change in YBOCS-SV scores by the pre-treatment standard
deviation (Becker, 1988). The YBOCS-SV was the outcome
measure of choice because it reports on both distress and
behaviors associated with CBD and has been shown to be
sensitive to change during CBD treatment (Monahan et al.,
1996). Although other CBD assessment measures are avail-
able (see Maraz et al., 2015 for examples), these measures
were not used here due to their absence in retrieved CBD
treatment studies.
Forest plots were then generated on STATA, com-
manded by Metan (Harris et al., 2008). Tests for heteroge-
neity were calculated using I2, a statistic that indicates the
percentage of variance in a meta-analysis attributable to study
heterogeneity (Higgins, Thompson, Deeks, & Altman, 2003).
Keywords inputted: “compulsive buy*’’ or ‘‘pathological buy*’’ or ‘‘shopping addict*’’ or 
‘‘oniomania’’ or ‘‘overspending’’ AND ‘‘treatment*’’  or ‘‘exp. psychotherapy’’ or 
‘‘intervention*’’
PsycINFO: 
609PubMed: 98
ISI Web of 
Knowledge: 244
Full-text articles 
screened for inclusion 
criteria: 225
201 excluded due to:
CBD not the primary 
focus of treatment
Multiple reports of the 
same study
No outcomes
From contacted 
authors: 4
Updated search 
(August 2015): 1
Included in the final 
review:  29
726 excluded due to:
Duplication
Not relevant
Not in English
Titles and abstracts 
screened: 951
Figure 1. Flowchart of the literature search process
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As this review was trying to estimate the combined effect of
sets of studies investigating the effectiveness of psychother-
apy and pharmacotherapy for CBD, there needed to be a
check that the effects found in the individual studies were
similar enough that the combined estimate was a meaningful
description. The I2 indicated whether there was more het-
erogeneity than would be expected by the chance alone.
To assess whether treatment duration was associated with
YBOCS-SV effect size for each type of treatment (psycho-
therapy, drug treatment, and placebo), a series of univariate
meta-regressions were conducted using the METAREG
macro (Wilson, 2005). Funnel plots of YBOCS-SV effect
sizes (plotted against the effect size standard error) were
used to check for publication bias (Egger, Smith, & Minder,
1997). Three separate funnel plots were produced for each
treatment type (psychotherapy, drug treatment, and place-
bo). Publication bias is indicated by visual asymmetry in
funnel plots, the absence of trials in the bottom corner of the
plot suggesting inﬂation of the population effect size esti-
mate (Higgins & Green, 2011).
RESULTS
Study characteristics
Table 1 summarizes the studies (N= 29) extracted for
this review, reporting total quality scores. Psychotherapy
(n= 17) and pharmacotherapy studies (n= 12) are presented
in two sections and studies are arranged by research meth-
odology consistent with identiﬁed stages of the hourglass
model. Studies that described both psychotherapy and
pharmacotherapy treatments (n= 2) were included in the
treatment arm that provided the greatest detail in the paper.
Table 2 summarizes the CBD treatments (n= 6) that have
been tested under conditions of high methodological quali-
ty, adjudged by scoring 17 or higher according to the Downs
and Black (1998) criteria.
Nine case reports constituted over half (53%) of the CBD
psychotherapy evidence base. Methodological quality was
generally poor across each of the quantitative case reports
(n= 8, M= 6.3, range 0–14, and 0 of 8 rated as high
quality). A notable exception was a cognitive behavioral
therapy (CBT) single case experimental design (SCED) that
scored on 8 of the 11 quality criteria on the CASP. The
qualitative case study on family therapy (n= 1) met only 4
of the 10 quality criteria on the CASP. Four effectiveness
studies were of varying quality (M= 11.6, range 6–18, and 1
of 4 rated as high quality) and testing group mindfulness-
based stress reduction (n= 1), CBT groups (n= 2), and
experiential therapy (n= 1). Four psychotherapy RCTs were
identiﬁed: (a) group self-control approach (n= 1); (b) group
CBT (n= 2); and (c) integrated group therapy (n= 1). RCTs
were generally of high quality (M= 18.0, range 9–23, and 3
of 4 rated as high quality; Table 2). No large-scale practice-
based research has been conducted (i.e., stage 3 of the
hourglass model).
For CBD pharmacotherapy treatment, six case reports
(50%) were extracted that tested tricyclic and selective
serotonin reuptake inhibitor (SSRI) antidepressants (n= 2),
an opioid receptor antagonist (n= 1), an NMDA-receptor
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antagonist (n =1), and anticonvulsants (n= 2). All case
reports were low quality (M= 4.7, range 3–6, and 0 of
6 rated as high quality). Two effectiveness studies were
found testing SSRI antidepressant (n= 1) and an NMDA-
receptor antagonist treatment (n= 1) and were rated equally
in quality (M= 13.0, range 13–13, and 0 of 2 rated as high
quality). The four RCTs conducted tested three types of SSRI
antidepressants and were of mixed quality (M= 14.0, range
8–19, and 1 of 4 rated as high quality; Table 2). Again, no
large practice-based outcome research (stage 3 of the hour-
glass model) was available.
Synthesis of the CBD psychotherapy evidence base
Case reports (stage 1 of the hourglass model). Ubiquitous
positive outcomes for compulsive buyers were reported in
case reports describing the psychoanalysis (Winestine,
1985), psychodynamic psychotherapy (Krueger, 1988), be-
havioral approaches (Bernik, Akerman, Amaral, & Braun,
1996; Donahue, Odlaug, & Grant, 2011), and cognitive-
behavioral approaches augmented with antidepressant med-
ication (Braquehais, Del Mar Valls, Sher, & Casas, 2012;
Marcˇinko & Karlovic´, 2005). Despite the encouraging
conclusions, these six case reports had common methodo-
logical ﬂaws and omissions, consistently lacking a standard-
ized measure to assess CBD and also an index of treatment
adherence. Moreover, all were inadequately described, ren-
dering the research vulnerable to many internal biases.
Of higher quality were a case report (Kellett & Bolton,
2009) and an SCED (Kellett & Robinson, 2009) describing
a 10-session cognitive-behavioral intervention that com-
prised planned avoidance, exposure and response preven-
tion, emotional regulation, and assertiveness training.
Clinically signiﬁcant change was shown on the YBOCS-
SV between assessment and termination, with no deteriora-
tion at 6-month follow-up. Both reports provided a clear
detail on CBT formulation and treatment, with the behav-
ioral measures in the SCED adding objectivity to outcome
assessment. Notably, the SCED (Kellett & Robinson, 2009)
provided a comparator with counseling, but this within-
subject control was undermined by an absence of statistical
comparisons between treatment phases. Again, external
validity was compromised in both reports by an absence
of the source of participant and practitioner qualiﬁcation.
Finally, qualitative evaluation of family therapy provided an
appropriate methodology to explore mechanisms of change
during CBD treatment (Salkovskis, 1995). Park, Cho, and
Seo (2006) evaluated family therapy via grounded theory, in
which a clear description of the 15-session treatment is
provided. Rigorous analysis was employed on session
transcripts, including a validation process by client feedback
and then by independent researchers. Conversely, no clear
information about the selection of compulsive buyers or a
clear statement of outcome was given. As with the other
case studies, these omissions compromise the generalizabil-
ity of the ﬁndings.
Effectiveness studies (stage 1 of the hourglass model).
All four effectiveness studies considered group treatment of
CBD. All studies reported signiﬁcant reductions in YBOCS-
SV scores or distress associated with CBD, but only one
group study (Mitchell, Burgard, Faber, Crosby, & de
Zwaan, 2006) was rated as high quality. Mitchell et al.
(2006) compared female participants assigned (non-
randomly) to either group CBT (n= 28) or wait-list (n=
11). Participants were screened using the Compulsive Buy-
ing Scale (CBS; Faber & O’Guinn, 1992) and excluded if
they had alcohol or drug dependence. CBT comprised
12-weekly sessions covering psychoeducation, cognitive
restructuring, ﬁnancial planning, and exposure techniques,
with between-sessions homework. Signiﬁcant pre–post and
pre-follow-up reductions were found in CBD episodes and
the money spent on consumer items. However, the consid-
erable attrition rates found at both recruitment (32%) and
during treatment (28%) question the acceptability of the
treatment. Although selection bias was uncontrolled through
a lack of randomization, internal validity was improved by
clear sourcing of participants, standardized assessment
tools, and intention-to-treat analysis on dropouts. In a
smaller CBT group pilot (N= 9), Filomensky and Tavares
(2009) delivered the same Mitchell et al. (2006) protocol
within an extended 20-week program to more actively target
CBD cognitions. Full attendance for the group (100%) and
signiﬁcant reductions in cognitive components of the
YBOCS-SV were reported post-treatment. Unlike Mitchell
et al. (2006), the authors failed to provide information
regarding the participants, the location, or the therapists
Table 2. High-quality CBD treatments and outcomes
CBD treatment (duration; components) Reference Sample (n); outcome
Group CBT (12 weeks) Mitchell et al. (2006) 28; signiﬁcant pre–post and pre-6-month-follow-up
reductions in YBOCS-SV
Stopping overshopping group (12-week
group program; CBT/MI/DBT/ACT)
Benson et al. (2014) 11; signiﬁcant pre–post and pre-6-month-follow-up
reductions in YBOCS-SV
Group CBT (12 weeks; Mitchell’s group program) Mueller et al. (2008) 60; signiﬁcant pre–post and pre-6-month-follow-up
reductions in YBOCS-SV
Group CBT (12 weeks) Müller et al. (2013) 22; signiﬁcant reductions in YBOCS-SV compared
with wait-list
Telephone-guided self-help (12 weeks) Müller et al. (2013) 20; signiﬁcant reductions in YBOCS-SV compared
with wait-list
SSRI antidepressant ﬂuvoxamine (8 weeks) Black et al. (2000) 24; no difference between drug and placebo in YBOCS-SV
Note. MI=motivational interviewing; DBT= dialectical behavior therapy; ACT= acceptance and commitment therapy.
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involved. Inadequate reporting therefore limited the explo-
ration of the results.
Klontz, Bivens, Klontz, Wada, and Kahler (2008)
reported intensive 6-day group programs with problem
spenders (N= 33), comprising ﬁnancial planning integrated
with the experiential therapy. Results indicated signiﬁcant
improvements in mood and reductions in problematic atti-
tudes toward buying at termination and at 3-month follow-
up. Caution must be applied to the ﬁndings, as no formal
measures were used to determine diagnosis beyond “money-
disordered behaviors.” Also, the external validity of the
experiential program was questionable, as participants were
required to stay at a retreat and engage in over 100 hr of
treatment. Armstrong (2012) employed a mixed methods
approach to monitor the effectiveness of a small sample
(n= 6) undertaking group mindfulness-based stress reduc-
tion (MBSR; Kabat-Zinn, 1982). Following the treatment,
clinically signiﬁcant change was found in YBOCS-SV
scores of the CBD group receiving MBSR. Interpretative
phenomenological analysis also revealed greater awareness
of physiological drives to buy, in addition to control over
emotional regulation when buying. Despite clear recruit-
ment and treatment procedures, lack of randomization and
opportunistic sampling rendered the sample vulnerable to
selection bias.
RCTs (stage 2 of the hourglass model). The four RCTs
completed also tested group treatment for CBD and were
largely (3 of 4) of high quality. The (low quality) exception
was the early Paulsen, Rimm, Woodburn, and Rimm (1977)
RCT. Participants (N= 19) were randomized to receive
either CBT groups that comprised reinforcement principles
and practical planning around buying (over 4 weeks) or a
placebo condition in which buying was discussed using
psychoanalytic constructs. Full attendance in the CBT
condition reﬂected high treatment acceptability. Conclu-
sions, however, are limited to a self-selected and non-
clinical sample. The lack of information regarding the
recruitment procedure also limits the external validity of
the ﬁndings.
Two (high quality) RCTs have tested the Mitchell et al.
(2006) group CBT approach. First, Mueller et al. (2008)
compared the 12-week program to a wait-list condition over
the same period. Compulsive buyers were recruited through
local advertising and assessed for CBD using a diagnostic
interview developed in previous CBD research (McElroy,
Keck, Pope, Smith, & Strakowski, 1994). Participants were
included only if they were stable on antidepressants for
3 months, but were excluded if they met criteria for manic
depression, or had current suicidal intent. Accordingly, only
12% did not meet the inclusion criteria. Eligible participants
(N= 60) were randomized to either group CBT or wait-list.
Those in the experimental condition showed improvement
on the YBOCS-SV and CBS post-treatment and at 6-month
follow-up. Müller, Arikian, de Zwaan, and Mitchell (2013)
not only employed a similar wait-list RCT design but also
used a low-intensity guided self-help (GSH) intervention as
an additional active control. Participants randomized to
GSH devoted time to reading a manual and completing
self-directed tasks (based on Mitchell et al., 2006) and were
also supported over the telephone at ﬁve time points over a
10-week period. Group CBT (n= 22) and GSH (n= 20)
participants showed a marked improvement in YBOCS-SV
scores compared with wait-list, with equivalent reliable
CBD change rates (45% in GSH group compared with
50% in CBT group). In both of these trials, standardized
outcome measures were used and differences in age and
severity were controlled for. Equally, intention-to-treat was
appropriately employed in both studies, considering attrition
rates of 19% (Mueller et al., 2008) and 27% (Müller et al.,
2013), respectively. Importantly, Mueller et al. (2008)
showed that attendance was a signiﬁcant predictor of
outcome.
Most recently, Benson, Eisenach, Abrams, and van
Stolk-Cooke (2014) developed the “stopping overshopping
program.” This program integrated CBT (Mitchell et al.,
2006; Mueller et al., 2008; Müller et al., 2013), acceptance
and commitment therapy, and psychodynamic principles. A
12-week pilot was conducted on a small sample (N= 11),
with a comparable recruitment process to the CBT group
RCTs. Secondary outcome measures assessed the potential
beneﬁt to known comorbid issues associated with CBD.
Clinically signiﬁcant reductions in CBS and YBOCS-SV
scores were reported in the CBD group (but not wait-list) at
termination, with additional reductions in associated item
hoarding. Similar to the CBT group RCTs, the inclusion of a
6-month follow-up period in the Benson et al. (2014) study
was a strength of the design, revealing durable gains for
compulsive buyers.
In summary, group psychotherapeutic treatment of CBD
in terms of delivery of adapted CBT, self-control strategies,
and eclectic approaches appears effective in reducing dis-
tress and maladaptive buying behavior associated with
CBD. The evidence suggests that treatment gains following
group intervention are durable. When group psychotherapy
outcomes have been compared with a low-intensity inter-
vention (one-to-one telephone GSH for CBD), effects ap-
pear comparable.
Synthesis of the CBD pharmacotherapy evidence base
Case reports (stage 1 of the hourglass model). Six case
reports describe positive conclusions from treating CBD
with tricyclic and SSRI antidepressants (McElroy et al.,
1994; McElroy, Satlin, Pope, Keck, & Hudson, 1991), a
course of the opioid antagonist, naltrexone with the aim of
reducing urges associated with CBD (Grant, 2003; Kim,
1998), and a 3-month treatment of the anticonvulsant topir-
amate with the rationale that it has shown some efﬁcacy with
mood disorders and obsessive and compulsive symptoms
(Guzman, Filomensky, & Tavares, 2007; Ye, Kadia, &
Lippmann, 2014). The case reports make a poor contribu-
tion to CBD pharmacotherapy outcome evidence base, as
outcomes in all but one report (Ye et al., 2014) were
unsupported by valid or reliable outcome measurement. All
case reports had in common a lack of sufﬁcient methodo-
logical control and the insufﬁcient detail in general reporting
would also greatly limit generalizability and replication.
Adverse effects also undermined the effectiveness of each
drug (McElroy et al., 1991, 1994).
Effectiveness studies (stage 1 of the hourglass model).
Two of the extracted pharmacotherapy studies employed a
pre–post design, with varied quality. Black et al. (1997)
Journal of Behavioral Addictions
Review of compulsive buying treatments
examined a 9-week course of ﬂuvoxamine (SSRI antide-
pressant) in an uncontrolled CBD sample (N= 10). Results
show signiﬁcant reductions in YBOCS-SV outcome scores
after placebo phase, with further reductions post-treatment.
The inclusion of a single-blind placebo phase in the Black
et al. (1997) study provided conditions to test the true effect
of the drug. However, no comparison was made between
improvement pace/rates in each phase, limiting conclusions
about continued effect of placebo in active treatment. Grant,
Odlaug, Mooney, O’Brien and Kim (2012) completed an
open-label study of the effectiveness of memantine (an
NMDA-receptor agonist used in the treatment of impulsivi-
ty). In the small uncontrolled sample (N= 9), signiﬁcant
improvements in YBOCS-SV scores between baseline and
end of treatment were reported. No follow-up data were
provided and so restricted any conclusions about durability
of memantine and the lack of a control group limited
treatment efﬁcacy comparisons. For both studies, inclusion
of the YBOCS-SV improved the internal validity of the
methodologies used, reﬂecting a progression from case
report methodology. The lack of information regarding the
recruitment procedures limits the conclusions concerning
generalizability.
RCTs (stage 2 of the hourglass model). Four RCTs
have tested the SSRI antidepressants citalopram (Koran,
Chuong, Bullock, & Smith, 2003), escitalopram (Koran,
Aboujaoude, Solvason, Gamel, & Smith, 2007), and ﬂu-
voxamine (Black et al., 2000; Ninan et al., 2000), producing
contrasting outcomes. Two comparable placebo-controlled
studies tested the efﬁcacy of ﬂuvoxamine to replicate Black
et al.’s (1997) ﬁndings under stricter methodological con-
ditions. In a high-quality study, Black et al. (2000) recruited
compulsive buyers (N= 24), who all ﬁrst received placebo
for 1 week in a ‘‘wash-out’’ phase. Participants were then
assigned to either ﬂuvoxamine or placebo for 8 weeks, with
weekly check-ups around side effects and dosage. Use of
standardized measures of CBD, randomization, and analysis
inclusive of dropouts minimized selection bias, improving
the internal validity of the ﬁndings. No differences were
found between ﬂuvoxamine and placebo; the clinically
signiﬁcant change rate (on YBOCS-SV scores) was greater
for placebo (55%) than ﬂuvoxamine (17%). Signiﬁcantly
greater symptoms of nausea, insomnia, decreased motiva-
tion, and sedation were found in the active drug treatment
arm. This method was replicated in a larger university
student-based study (N= 42) over a 13-week period (Ninan
et al., 2000). No signiﬁcant differences were found between
treatment and placebo in domains of CBD distress, general
functioning, and depression. High attrition rates (45%)
occurred from recruitment, with a further eight participants
(19%) dropping out due to the adverse side effects from
taking Fluoxetine. Failure to report the characteristics of
these participants limited conclusions about the potential
harms of treatment. The initial promising ﬁndings for the
SSRI ﬂuvoxamine were subsequently not conﬁrmed in high-
quality trials, in which experience of side effects appeared
common and prominent.
Koran et al. (2003, 2007) completed equivalent double-
blind discontinuation trials of the SSRI’s citalopram (N=
24) and escitalopram (N= 26), respectively. Participants
were randomized to a 9-week discontinuation phase of
placebo or drug treatment, following a 7-week open-label
phase. Koran et al. (2003) found reductions in YBOCS-SV
scores after open-label treatment. Further improvements
were reported in the citalopram group following the discon-
tinuation phase (though non-signiﬁcant), while YBOCS-SV
scores in the placebo group were signiﬁcantly deteriorated.
In the Koran et al. (2007) replication study, ﬁndings were
reversed for escitalopram. In both trials, weekly consulta-
tions monitored drug dosages across study phases. Internal
validity was improved from antidepressant case reports
(McElroy et al., 1991, 1994) due to the presence of ran-
domization and standardized assessment procedures, out-
come monitoring, and the exclusion of participants with
comorbid presentations. Substantial relapse rates (deﬁned
by scores over 16 on the YBOCS-SV) were found after the
discontinuation phase in both the escitalopram arm (63%)
and placebo arm (67%). In both studies, a signiﬁcant
number met responder status by the end of open-label
treatment, indicating a large placebo effect prior to random-
ization. Promising ﬁndings for citalopram in Koran et al.
(2003) requires further study. Conversely, a marked im-
provement from the open-label phase Koran et al. (2007)
failed to conﬁrm true drug effects of escitalopram. Failure to
detail safeguards for blinding both the researchers and the
participants suggests that vulnerability to these internal
biases could account for contrasting outcomes.
Effect of psychotherapy and pharmacotherapy treatments
on CBD
Effect sizes were calculated for appropriate CBD treatment
studies, with a pre–post effect being employed due to the
large proportion of uncontrolled studies (67%). Fourteen
CBD treatments met the criteria for inclusion (within 10
CBD studies). Effect sizes were then divided into CBD
psychotherapy (n= 6) and CBD pharmacotherapy (n= 8)
interventions, with the latter subdivided into active treat-
ment (n= 5) and placebo (n= 3).
Effect of psychotherapy intervention. Figure 2 illustrates
an overall uncontrolled effect size for psychotherapy
CBD treatments (n= 6) of d= 1.51 (95% CI= 1.18–1.84),
p< .001. Although a range of psychotherapeutic approaches
were delivered, tests for heterogeneity showed non-signiﬁ-
cant differences (I2= 8.04, df= 5, p= .154), indicating that
psychotherapy for CBD were homogenous. Group CBT
studies contributed most of the weighting (72.8%) in the
large effect size found. The GSH active control arm in the
(high quality) Müller et al. (2013) trial produced an equiva-
lent outcome effect to group CBT. Figure 4 (top) shows the
funnel plot for the CBD psychotherapy outcome studies.
Observed asymmetry indicates that less precise (smaller)
psychotherapy studies with non-signiﬁcant ﬁndings may not
have been published. This therefore suggests that treatment
effect size estimates for psychotherapy for CBD reported
may represent an overestimation of the effect. Meta-regres-
sion found that duration of psychotherapy was not signiﬁ-
cantly associated with CBD treatment effects (β=−0.28,
z=−1.33, p= not signiﬁcant).
Effect of pharmacotherapy intervention. Figure 3
illustrates the effect sizes for pharmacotherapy CBD
treatments and placebo comparisons, respectively. The
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Koran et al. (2007) study on escitalopram effect size was not
calculated due to the lack of reported outcomes in the post-
discontinuation phase. Overall, pharmacological treatments
(n= 5) produced an uncontrolled effect size of d= 1.84
(95% CI= 1.27–2.40), p< .001. Placebo controls within the
same studies (n= 3) produced an equivalent effect of d=
1.26 (95% CI= 0.59–1.93), p< .001. This overlap between
drug and placebo conﬁdence intervals suggests a non-sig-
niﬁcant difference between active and placebo CBD drug
treatments. The poor methodological quality of the outcome
studies of ﬂuvoxamine (Black et al., 1997; Ninan et al.,
2000) and memantine (Grant et al., 2012) undermines the
large effect size found. Black et al.’s (2000) trial revealed
the comparable effects of placebo to ﬂuvoxamine. However,
during the double-blind phase, Koran et al.’s (2003) study
effects demonstrate the maintenance of clinical effects with
citalopram, and not placebo (Figure 3). The differences in
methodological quality, sample size, and intervention con-
tributed to signiﬁcant heterogeneity being found across
active drug treatments (I2= 14.47, df= 4, p= .006) and
placebo (I2= 22.85, df= 2, p< .001). Asymmetry in the
drug treatment funnel plot (Figure 4, middle) indicates that
less precise drug treatment studies, with non-signiﬁcant
ﬁndings, may not have been published resulting in an
overestimation of treatment effects. As expected, given the
small number of placebo studies assessed, the corresponding
funnel plot (Figure 4, bottom) was also asymmetrical. It is,
therefore, likely that publication bias also affected the effect
size estimate for CBD placebo studies. Duration of drug
treatment was signiﬁcantly associated with CBD outcome
(β= 0.69, z= 7.48, p< .001), as was the duration of the
placebo period (β= 0.53, z= 8.64, p< .001). Therefore,
longer drug treatments and placebo periods were both
associated with improved CBD treatment outcomes.
In summary, the large effects in studies of high method-
ological quality for group psychotherapy and also GSH for
CBD indicate the promise of such approaches. In contrast,
the synthesis and effect sizes for pharmacotherapy CBD
treatments highlighted a mismatch between the effective-
ness of the intervention and the quality of the study con-
ducted, with the possible exception of Koran et al.’s (2003)
citalopram study. Caution is indicated regarding the inter-
pretation of all the calculations across type of CBD inter-
vention as (a) uncontrolled effect sizes are often larger than
the controlled effects (Field, 2005) and (b) large effect sizes
are potentially compromised once poor acceptability, un-
known durability and poor treatment model ﬁdelity are
considered.
DISCUSSION
This review assessed the standing, progression, and out-
comes of the CBD psychotherapy and pharmacotherapy
treatment evidence bases. This review used the Salkovskis
(1995) hourglass model as a framework for treatment
research progression, whereby externally valid small N
practice-based research are the foundation stone for con-
trolled trials whose external validity is then tested again in
large N practice-based research. This systematic and meta-
analytic review of the CBD outcome research draws the
following conclusions: (a) the evidence base for CBD
Figure 2.Uncontrolled effect sizes for CBD psychotherapy. ES = effect size and 95% CI; % weight = sample size determines the weighting of
each study toward the overall ES; GSH = guided self-help (control) condition
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treatments is somewhat undermined by inconsistent study
quality and the risk of publication bias; (b) both psycho-
therapy and pharmacotherapy treatments have been studied
somewhat haphazardly and sporadically across the stages of
the hourglass model; (c) large pre–post effect sizes in high-
quality studies of group psychotherapy show the promise of
this approach; (d) large uncontrolled effect sizes for drug
treatments are undermined by poor methodological quality;
(e) there appears a signiﬁcant placebo effect when treating
CBD with medication; and ﬁnally, (f) the lack of large-scale
practice-based studies (stage 3 of the hourglass) is appro-
priate, given the paucity of controlled psychotherapy and
pharmacotherapy outcome studies at stage 2 of the hourglass
model.
Figure 3. Uncontrolled effect sizes for CBD pharmacotherapy and placebo. ES = effect size and 95% CI; % weight = sample size determines
the weighting of each study toward the overall ES
Journal of Behavioral Addictions
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Clinical implications
Group psychotherapy that primarily adopts a cognitive-
behavioral approach, or use the cognitive-behavioral ap-
proach nested within an eclectic approach appear to be
useful and have a durable effect in reducing distress associ-
ated with CBD and maladaptive buying behavior. Group
treatments have shown to be effective with other impulse
control disorders such as pathological gambling (Cowlishaw
et al., 2012) and intermittent explosive disorder
(McCloskey, Noblett, Deffenbacher, Gollan, & Coccaro,
2008). Recent experimental evidence suggests that impulse
control training should be a core component of CBD treat-
ment (Hague, Kellett, & Sheeran, 2016). It is worth noting
that attrition rates show that group psychotherapy may not be
an acceptable approach for all CBD patients, and that patient
choice and suitability are also still important considerations.
Results also need to be considered in light of the stepped
care delivery model for psychological interventions (Bower &
Gilbody, 2005). This is because the evidence suggests that a
low-intensity GSH approach to treating CBD was compar-
ative to high-intensity group CBT. If patients can be treated
with effective, brief, and less intensive psychological inter-
vention ﬁrst, then this can increase service throughput and
efﬁciency (Firth, Barkham, & Kellett, 2015). Investigation
of contemporary interventions such as internet-based thera-
pist-assisted self-help programs also usefully mimic the shift
of consumer behavior toward online shopping (Ridgeway,
Kukar-Kinney, & Monroe, 2011). Recent research shows
that excitability regarding online shopping and CBD are
mediated by internet use expectancies (Trotzke, Starcke,
Müller, & Brand, 2015). Treatments clearly need to reﬂect
the context within which CBD occurs.
Large effect sizes were found for SSRI antidepressant
medication. However, SSRIs did not show signiﬁcant su-
periority in terms of efﬁcacy when treating CBD compared
with placebo. Interestingly, the SSRI’s citalopram and
escitalopram (which share the same active compound)
showed contradictory ﬁndings. Further high-quality re-
search into the role of SSRIs in treating CBD is required;
particularly as these studies currently constitute a large
proportion of the current pharmacotherapy evidence base.
Greater detail and consistency in reporting outcomes in
studies are also highlighted by the lack of effect size
calculations in Koran et al.’s (2007) study. Controlled
studies of ﬂuvoxamine showed no greater beneﬁt than
placebo in treating CBD. The apparent mismatch between
large effect sizes and poor quality of SSRI outcome studies
particularly emphasizes the importance of consistent utili-
zation of robust outcome methodologies in future CBD
pharmacotherapy outcome research. Longer treatments ap-
pear associated with improved treatment outcomes when
using pharmacotherapy to treat CBD and less when deliv-
ering psychotherapy. Why this longitudinal relationship is
the case demands further investigation. Harm in terms of
side effects and risk of dropout also needs to be carefully
considered in relation to the pharmacotherapy of CBD.
A lack of clarity remains in the comparison of psycho-
therapeutic and pharmacological interventions for CBD.
This is because there is a paucity of sufﬁciently sized trials
comparing psychotherapies and pharmacotherapies with
Figure 4. Funnel plots of YBOCS-SV effect sizes for studies
included in the forest plot analyses (k = 14), broken down by the
treatment type assessed: psychotherapy (top), drug treatment
(middle), and placebo (bottom)
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themselves and between each other. There is less utility in
conducting more passive control wait-list control trials of
psychotherapeutic interventions for CBD (more use of
active treatment controls is indicated) and conversely the
need for more double-blind placebo-controlled trials in
pharmacological treatment evidence base. Researchers need
to consider randomizing participants to types of psychother-
apy following the initial pharmacotherapy (and vice versa).
The current CBD evidence base would suggest that clin-
icians should initially consider a psychotherapeutic treat-
ment option, prior to starting pharmacotherapy. This is
because ES metrics should always be considered in the
context of the quality of the evidence base. The group
psychotherapy effects were found in the context of studies
with sufﬁcient methodological quality.
Scientiﬁc state of the CBD treatment evidence
Low-quality case reports constitute a worryingly large pro-
portion of CBD treatment evidence base. According to the
hourglass model, initial practice-based designs are essential
in developing clinical concepts, but are then required to the
rigorously tested and reﬁned under strict methodological
conditions (Salkovskis, 1995). The CBD evidence base is
therefore unbalanced by the number of stage 1 type studies,
which have additionally not proven the stimulus or founda-
tion stone for future detailed and controlled inquiry. The
small numbers of subsequent stage 2 high-quality studies
(i.e., randomized and controlled) means that efﬁcacy of CBD
treatments has not been extensively tested. No treatment
component analyses have been conducted at stage 2, so that
identifying the active ingredients of CBD treatments has been
hindered. Due to trials having strict inclusion and exclusion
criteria, then CBD participants with comorbid presentations
have tended to be excluded. No large-scale stage 3 service
evaluations have been attempted and this would seem appro-
priate given the need for more model-speciﬁc stage 1 and 2
evidence as the foundation stone upon which such studies
could be based. Future research should endeavor to utilize the
hourglass model in order to target treatments and methodol-
ogies at appropriate stages to enhance the CBD evidence
base. For some psychotherapy modalities (particularly more
interpersonal/psychodynamic approaches), it would be a
mistake to rush into conducting a trial.
When speciﬁc CBD treatments were isolated for analysis,
then this review highlights that they have typically been
studied sporadically across the stages of the hourglass model.
Of the ﬁfteen different treatment modalities extracted, only
group CBT and SSRI antidepressant interventions had pro-
gressed through more than one stage. The vital importance of
the connected progression of outcome research is typiﬁed by
SSRI antidepressant outcome studies (Black et al., 2000;
Koran et al., 2007), where poor efﬁcacy and harm were only
highlighted when the complexity of methodological designs
were reﬁned and improved. Stage 1 studies can unwittingly
and artiﬁcially inﬂate the assumed safety and effectiveness of
an intervention. The common inconsistency of study quality
indicates the potential presence of a consistent “type-I error”
as well as the under-reporting of negative outcomes and the
potential for publication bias.All studies and across treatment
types need to pay more attention to recording untoward
incident and harm rates during treatment. This neglect in the
effective sequencing of exploration, reﬁning, and generaliz-
ing of CBD treatments has the potential to signiﬁcantly
compromise patient care (Salkovskis, 1995).
Future research
Revisiting the initial stages of the hourglass model is clearly
required using mixed methods approaches to enhance the
CBD outcome evidence. The potential danger of false-
positive outcomes can be addressed with robust outcome
measurement and detailed information regarding partici-
pants and treatments. SCEDs offer an empirical framework
to develop CBD practice-based evidence with minimal
restrictions over the service setting (McMillan & Morley,
2010). Moreover, the ﬂexibility inherent to SCED makes it
well placed to acknowledge the complexities of CBD
(Barkham, Hardy, & Mellor‐Clark, 2010). On comprehen-
sive stage 1 evidence, then future trials at stage 2 need to
compare individual versus group psychotherapy for CBD.
Qualitative research has the potential to enhance the under-
standing of high dropout rates evidenced during group
psychotherapy of CBD, by exploring the patient experience
of treatment. Furthermore, qualitative methodology offers
the possibility of deﬁning the common and shared features
of CBD treatments (Denzin & Lincoln, 2000). Understand-
ing the active components of effective CBD psychotherapy
is a key research goal, using dismantling or additive trial
methodologies at the second stage of the hourglass. Robust
stages 1 and 2 evidence would enable practice-based re-
search networks to ﬂourish across services (Zarin, West,
Placus, & McIntyre, 1996).
The promising ﬁndings from the controlled study of
citalopram (Koran et al., 2003) and uncontrolled studies of
topiramate (Guzman et al., 2007), naltrexone (Grant, 2003;
Kim, 1998), and memantine (Grant et al., 2012) require
further scrutiny under large sample RCT conditions. This
comment also applies to substantiate the initial claims
regarding the effectiveness of MBSR for CBD (Armstrong,
2012). More controlled research comparing low- and high-
intensity psychological interventions needs to be conducted.
Future outcome research needs to consistently use the
YBOCS-SV (Monahan et al., 1996) as the primary outcome
measure and then consistently report treatment response
rates using common clinical and reliable change metrics.
The size of future trials needs to be increased in order to
reduce the possibility of publication bias and reduce the
potential confound of a “small study effect” in future
reviews (Rücker, Carpenter, & Schwarzer, 2011). Finally,
follow-up across the psychotherapeutic and pharmacologi-
cal studies tended to be short and so future studies need
genuinely long-term follow-up periods to assess the dura-
bility of treatment effects.
Limitations
This review had several limitations. First, the large number
of poor quality studies failed to use any standardized
outcome measurement (38%) and this compromised calcu-
lating CBD treatment effects across a wide range of studies.
Interpretations regarding the efﬁcacy and effectiveness of
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CBD treatments were limited by consistently small sample
sizes, poor methodological control, a variety of treatment
approaches, and risk of publication bias. The inter-rater
reliability of the CASP was weak and the lack of a deﬁned
quality cutoff compromises its utility. Nevertheless, this
review represents a step forward from Lourenço Leite
et al.’s (2014) review, due to better consideration of study
quality and greater analytical speciﬁcity.
CONCLUSIONS
The CBD treatment evidence base is clearly a work in
progress. Progress has been jointly hindered by the consistent
use of poor quality methodologies and the sporadic evaluation
of treatments. Greater effort in developing and evaluating
interventions in keeping with the hourglass model will
improve understanding of the potential beneﬁts and risks of
CBD treatments. The promise shown by high-quality group
interventions indicate a need to explore what it is about group
CBT approach that is particularly useful and a component
analysis of group CBT for CBD is particularly indicated. Less-
intrusive GSH treatments for CBD appear to hold clinical
promise and are suitable for detailed inquiry. SSRI citalopram
requires further controlled study to build on promising out-
comes. Clearly, CBD remains an under-recognized and chal-
lenging clinical disorder to treat. Ensuring and improving the
methodological quality of future studies will improve conﬁ-
dence in the initial evidence that compulsive buyers can
manage their compulsions to spend through relatively short-
term theory-based psychotherapeutic interventions.
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